Breztri (Budesonide, Glycopyrrolate, and Formoterol fumarate) for COPD

Overview
Breztri is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as long-term, daily maintenance treatment for airflow obstruction in people with chronic obstructive pulmonary disease (COPD). Breztri is a combination drug composed of Budesonide, Glycopyrrolate, and Formoterol fumarate.

Budesonide is a corticosteroid, a drug that dilates the bronchi and bronchioles in the lungs, making it easier to breathe. Glycopyrrolate is an anticholinergic. Formoterol fumarate is a long-acting beta2-adrenergic agonist (LABA). All three drugs are believed to work by relaxing and dilating the airways, making it easier to breathe.

How do I take it?
Breztri is taken twice daily.

Breztri comes in the form of an inhalation spray packaged in the special Aerosphere device.

Side effects
The FDA-approved label for Breztri lists common side effects including upper respiratory infection, pneumonia, back pain, influenza, yeast infections in the mouth, muscle spasm, cough, diarrhea, and sinus infection.

Rare but serious side effects listed for Breztri can include paradoxical bronchospasm (bronchospasm caused by taking medication), worsening narrow-angle glaucoma, urinary retention, changes in blood glucose or electrolyte levels, hypersensitivity reaction, and decreased bone density.

For more details about this treatment, visit:
Breztri — AstraZeneca
https://breztrihcp.com/